在2023系列中，我们通过亚洲妇科肿瘤学会回顾课程会议的交流，总结了妇科肿瘤学的主要临床研究进展。审查内容包括1）子宫内膜癌：免疫检查点抑制剂、抗体药物偶联物（ADC）、选择性核输出抑制剂、CDK4/6抑制剂、WEE1抑制剂、聚（ADP-核糖）聚合酶（PARP）抑制剂。 2）宫颈癌：低危早期宫颈癌的手术，局部晚期和晚期、转移性或复发性宫颈癌的治疗； 3) 卵巢癌：免疫疗法、使用免疫检查点抑制剂以及抗血管生成剂和 PARP 抑制剂的三联疗法以及 ADC。 2023 年，子宫内膜癌治疗领域见证了具有里程碑意义的一年，其标志是免疫检查点抑制剂带来的多项改变实践的成果以及 PARP 抑制剂和 ADC 的可靠疗效。© 2024。亚洲妇科肿瘤学会、韩国妇科肿瘤学会、和日本妇科肿瘤学会。

In the 2023 series, we summarized the major clinical research advances in gynecologic oncology based on communications at the conference of Asian Society of Gynecologic Oncology Review Course. The review consisted of 1) Endometrial cancer: immune checkpoint inhibitor, antibody drug conjugates (ADCs), selective inhibitor of nuclear export, CDK4/6 inhibitors WEE1 inhibitor, poly (ADP-ribose) polymerase (PARP) inhibitors. 2) Cervical cancer: surgery in low-risk early-stage cervical cancer, therapy for locally advanced stage and advanced, metastatic, or recurrent setting; and 3) Ovarian cancer: immunotherapy, triplet therapies using immune checkpoint inhibitors along with antiangiogenic agents and PARP inhibitors, and ADCs. In 2023, the field of endometrial cancer treatment witnessed a landmark year, marked by several practice-changing outcomes with immune checkpoint inhibitors and the reliable efficacy of PARP inhibitors and ADCs.© 2024. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.